Evaluation of endocrine changes in women with the polycystic ovary syndrome during metformin treatment

Bosnian Journal of Basic Medical Sciences

Volumn 13, Issue 3, 2013, Pages 180-185

  Velija Ašimi, Zelija ^a  

^a University Clinical Centre of Sarajevo   (Bosnia and Herzegovina)

Author keywords

Endocrine changes; Metformin treatment; Pcos

Indexed keywords

ANTIDIABETIC AGENT; ESTRADIOL; FOLLITROPIN; METFORMIN; PROGESTERONE; PROLACTIN; TESTOSTERONE;

ADULT; ANOVULATION; ANTHROPOMETRY; ARTICLE; BIOSYNTHESIS; BLOOD; BODY MASS; DRUG EFFECT; ENDOCRINE SYSTEM; FEMALE; HUMAN; INSULIN RESISTANCE; OVARY POLYCYSTIC DISEASE; YOUNG ADULT;

ADULT; ANOVULATION; ANTHROPOMETRY; BODY MASS INDEX; ENDOCRINE SYSTEM; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METFORMIN; POLYCYSTIC OVARY SYNDROME; PROGESTERONE; PROLACTIN; TESTOSTERONE; YOUNG ADULT;

EID: 84883643459     PISSN: 15128601     EISSN: 18404812     Source Type: Journal    
DOI: 10.17305/bjbms.2013.2359     Document Type: Article

References (29)

1. Pastor CL, Griffin-Korf ML, Aloi JA, Evans WS, Marshall JC. Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab. 1998;83(2):582-590.
2. McCartney CR, Eagleson CA, Marshall JC. Regulation of gonado-tropin secretion: implications for polycystic ovary syndrome. Semin Reprod Med. 2002; 20(4)317-326.
3. Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 2004; 89:453-462.
4. Carmina E, Orio F, Palomba S, Longo RA, Lombard G, Lobo RA. Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parameters. Fertil Steril. 2005; 84(2):413-419.
5. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81(1):19-25.
6. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41-47.
7. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003:9:505-514.
8. Azziz, R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Esco-bar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab 2006; 91:4237-4245.
9. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89:2745-2749.
10. Norman RJ, Noakes M, Wu R, Davies MJ, Moran L, Wang JX. Improving reproductive performance in overweight/obese women with effective weight management. Hum Reprod Update 2004; 10:267-280.
11. Dunaif A, Segal K, Futterweit W, Dobrjansky A. Profound peripheral resistance independent of obesity in polycystic ovary syndrome. Diabetes 1989; 38:1165-1174.
12. Badawy A, Elnashar A. Treatment options for polycystic ovary syndrome. Int J Womens Health. 2011; 3:25-35.
13. Geller D, Pacaud D, Gordon C, Misra M. Emerging Therapies: the use of insulin sensitizers in the treatment of adolescents with polycystic ovary syndrome (PCOS). Int J Pediatr Endocrinol. 2011; 2011:9.
14. Palomba S, Falbo A, Zullo F, Orio F Jr. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev. 2009; 30(1):1-50.
15. Fryer LG, Parbu-Patel A, Carling D. The Anti-diabetic drugs rosi-glitazone and metformin stimulate AMP-activated protein kinase through distinct signalling pathways. J Biol Chem 2002 Jul 12; 277(28): 25226-25232.
16. La Marca A, Artensio AC, Stabile G, Volpe A. Metformin treatment of PCOS during adolescence and the reproductive period. Eur J Obstet Gynecol Reprod Biol 2005;121 (1)3-7.
17. Vanky E, Stridsklev S, Heimstad R, Romundstad P, Skogoy K, Kleggetveit O., et al. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. J Clin Endocrinol Metab. 2010; 95(12): E448-455.
18. McFarland C. Treating polycystic ovary syndrome and infertility. MCN Am J Matern ChildNurs.2012;37(2):116-121.
19. Norman RJ. Editorial: Metformin--comparison with other therapies in ovulation induction in polycystic ovary syndrome. J Clin Endocrinol Metab. 2004; 89(10):4797-800.
20. Salley KE, Wickham EP, Cheang KI, Essah PA, Karjane NW, Nestler JE. Glucose intolerance in polycystic ovary syndrome-a position statement of the Androgen Excess Society. Clin Endocrinol Metab. 2007;92(11):4546-4556.
21. Mathur R, Alexander CJ, Yano J, Trivax B, Azziz R. Use of metformin in polycystic ovary syndrome. Am J Obstet Gynecol. 2008;199(6):596-609.
22. Salpeter SR, Buckley NS, Kahn JA, Salpeter EE. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med 2008;121:149-157.
23. Badawy A, Elnashar A. Treatment options for polycystic ovary syndrome. Int J Womens Health 2011;3:25-35.
24. Nestler JE. Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med. 2008; 358:47-54.
25. Tosca L, Rame C, Chabrolle C, Tesseraud S, Dupont J. Metformin decreases IGF1-induced cell proliferation and protein synthesis through AMP-activated protein kinase in cultured bovine granulosa cells. Reproduction 2010:139:409-418.
26. Bilk E, Kapolla N, Nicopoulou SC, Koukkou E, Venaki E, Milingos S., et al. Metformin administration was associated with a modification of LH, prolactin and insulin secretion dynamics in women with polycystic ovarian syndrome. Gynecol Endocrinol. 2009;25(7):427-434.
27. Palomba S, Falbo A, Carrillo L, Villani MT, Orio F, Russo T., et al.; METformin in High Responder Italian Group. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertil Steril. 2011;96(6):1384-1390
28. Palomba S, Falbo A, Russo T, Di Cello A, Morelli M, Orio F., et al. Metformin administration in patients with polycystic ovary syndrome who receive gonadotropins for in vitro fertilization cycles: 10-year experience in a large infertile population. Gynecol Endocrinol. 1012;28(2):81-86.
29. Rotondi M, Cappelli C, Magri F, Botta R, Dionisio R, Iacobello C, De Cata P, Nappi RE, Castellano M, Chiovato L. Thyroidal Effect of Metformin Treatment in Patients With Polycystic Ovary Syndrome. Clin Endocrinol 2011;75(3):378-38.